|
1
|
Dias F, Teixeira AL, Santos JI, Gomes M,
Nogueira A, Assis J and Medeiros R: Renal cell carcinoma
development and miRNAs: A possible link to the EGFR pathway.
Pharmacogenomics. 14:1793–1803. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Redova M, Svoboda M and Slaby O: MicroRNAs
and their target gene networks in renal cell carcinoma. Biochem
Biophys Res Commun. 405:153–156. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mishra PJ: MicroRNAs as promising
biomarkers in cancer diagnostics. Biomark Res. 2:192014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hao JF, Ren KM, Bai JX, Wang SN, Shao B,
Cao N and Li X: Identification of potential biomarkers for clear
cell renal cell carcinoma based on microRNA-mRNA pathway
relationships. J Cancer Res Ther. 10(Suppl): C167–C177. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang L, Xul B, Chen S, Lu K, Liu C, Wang
Y, Zhao Y, Zhang X, Liu D and Chen M: The complex roles of
microRNAs in the metastasis of renal cell carcinoma. J Nanosci
Nanotechnol. 13:3195–3203. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu W, Xu Z, Zhang M and Zuo Y: MiR-19a
promotes epithelial-mesenchymal transition through PI3K/AKT pathway
in gastric cancer. Int J Clin Exp Pathol. 7:7286–7296.
2014.PubMed/NCBI
|
|
7
|
Feng Y, Liu J, Kang Y, He Y, Liang B, Yang
P and Yu Z: miR-19a acts as an oncogenic microRNA and is
up-regulated in bladder cancer. J Exp Clin Cancer Res. 33:672014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jia Z, Wang K, Zhang A, Wang G, Kang C,
Han L and Pu P: miR-19a and miR-19b overexpression in gliomas.
Pathol Oncol Res. 19:847–853. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hao M, Zang M, Wendlandt E, Xu Y, An G,
Gong D, Li F, Qi F, Zhang Y, Yang Y, et al: Low serum miR-19a
expression as a novel poor prognostic indicator in multiple
myeloma. Int J Cancer. 136:1835–1844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li X, Xie W, Xie C, Huang C, Zhu J, Liang
Z, Deng F, Zhu M, Zhu W, Wu R, et al: Curcumin modulates
miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7
breast cancer cell proliferation. Phytother Res. 28:1553–1560.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qian CN, Furge KA, Knol J, Huang D, Chen
J, Dykema KJ, Kort EJ, Massie A, Khoo SK, Vanden Beldt K, et al:
Activation of the PI3K/AKT pathway induces urothelial carcinoma of
the renal pelvis: Identification in human tumors and confirmation
in animal models. Cancer Res. 69:8256–8264. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vranić S, Bilalović N, Lee LM, Kruslin B,
Lilleberg SL and Gatalica Z: PIK3CA and PTEN mutations in adenoid
cystic carcinoma of the breast metastatic to kidney. Hum Pathol.
38:1425–1431. 2007. View Article : Google Scholar
|
|
13
|
Fujiki K, Inamura H and Matsuoka M:
Detrimental effects of Notch1 signaling activated by cadmium in
renal proximal tubular epithelial cells. Cell Death Dis.
5:e13782014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ai Q, Ma X, Huang Q, Liu S, Shi T, Zhang
C, Zhu M, Zhang Y, Wang B, Ni D, et al: High-level expression of
Notch1 increased the risk of metastasis in T1 stage clear cell
renal cell carcinoma. PLoS One. 7:e350222012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang T, Han G, Wang Y, Chen K and Sun Y:
MicroRNA expression profiles in supraglottic carcinoma. Oncol Rep.
31:2029–2034. 2014.PubMed/NCBI
|
|
16
|
Zhi F, Shao N, Wang R, Deng D, Xue L, Wang
Q, Zhang Y, Shi Y, Xia X, Wang S, et al: Identification of 9 serum
microRNAs as potential noninvasive biomarkers of human astrocytoma.
Neuro Oncol. Epub ahead of print. Aug 18–2014.PubMed/NCBI
|
|
17
|
Sochor M, Basova P, Pesta M, Dusilkova N,
Bartos J, Burda P, Pospisil V and Stopka T: Oncogenic microRNAs:
miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early
breast cancer in serum. BMC Cancer. 14:4482014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu M, Bardia A, Aceto N, Bersani F, Madden
MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, et al:
Cancer therapy. Ex vivo culture of circulating breast tumor cells
for individualized testing of drug susceptibility. Science.
345:216–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yaeger R, Cowell E, Chou JF, Gewirtz AN,
Borsu L, Vakiani E, Solit DB, Rosen N, Capanu M, Ladanyi M, et al:
RAS mutations affect pattern of metastatic spread and increase
propensity for brain metastasis in colorectal cancer. Cancer.
121:1195–1203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne
D, Chakrabarti A, Bosma T, Fellowes A, Dobrovic A, et al kConFab
Investigators: Mutational profiling of familial male breast cancers
reveals similarities with luminal A female breast cancer with rare
TP53 mutations. Br J Cancer. 111:2351–2360. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tian L, Fang YX, Xue JL and Chen JZ: Four
microRNAs promote prostate cell proliferation with regulation of
PTEN and its downstream signals in vitro. PLoS One. 8:e758852013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu QQ, Wu H, Huang X, Shen H, Shu YQ,
Zhang B, Xiang CC, Yu SM, Guo RH and Chen L: MiR-1 targets PIK3CA
and inhibits tumorigenic properties of A549 cells. Biomed
Pharmacother. 68:155–161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Tang Q, Li M, Jiang S and Wang X:
MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.
Biochem Biophys Res Commun. 444:199–204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiao W, Chen X and He M: Inhibition of the
Jagged/Notch pathway inhibits retinoblastoma cell proliferation via
suppressing the PI3K/Akt, Src, p38MAPK and Wnt/β-catenin signaling
pathways. Mol Med Rep. 10:453–458. 2014.PubMed/NCBI
|
|
25
|
Sato A, Nagase H, Obinata D, Fujiwara K,
Fukuda N, Soma M, Yamaguchi K, Kawata N and Takahashi S: Inhibition
of MMP-9 using a pyrroleimidazole polyamide reduces cell invasion
in renal cell carcinoma. Int J Oncol. 43:1441–1446. 2013.PubMed/NCBI
|
|
26
|
Cho NH, Shim HS, Rha SY, Kang SH, Hong SH,
Choi YD, Hong SJ and Cho SH: Increased expression of matrix
metalloproteinase 9 correlates with poor prognostic variables in
renal cell carcinoma. Eur Urol. 44:560–566. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liang L, Li L, Zeng J, Gao Y, Chen YL,
Wang ZQ, Wang XY, Chang LS and He D: Inhibitory effect of silibinin
on EGFR signal-induced renal cell carcinoma progression via
suppression of the EGFR/MMP-9 signaling pathway. Oncol Rep.
28:999–1005. 2012.PubMed/NCBI
|
|
28
|
Li D, Masiero M, Banham AH and Harris AL:
The notch ligand JAGGED1 as a target for anti-tumor therapy. Front
Oncol. 4:2542014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Murea M, Park JK, Sharma S, Kato H,
Gruenwald A, Niranjan T, Si H, Thomas DB, Pullman JM, Melamed ML,
et al: Expression of Notch pathway proteins correlates with
albuminuria, glomerulosclerosis, and renal function. Kidney Int.
78:514–522. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leong KG and Karsan A: Recent insights
into the role of Notch signaling in tumorigenesis. Blood.
107:2223–2233. 2006. View Article : Google Scholar
|
|
31
|
Wu K, Zhang L, Lin Y, Yang K and Cheng Y:
Inhibition of γ-secretase induces G2/M arrest and triggers
apoptosis in renal cell carcinoma. Oncol Lett. 8:55–61.
2014.PubMed/NCBI
|
